Welcome to Our Skin, a Personal Discovery Podcast. Each week, host Holly Frey showcases a personal story from someone who lives–and thrives!--while managing psoriasis. Being diagnosed with a chronic skin condition can throw anyone off track, but Our Skin guests have a message of hope: a diagnosis can be an opportunity to discover new things about ourselves, our grit, and our power. In addition to these tales of hope, Frey and her guests plunge into the jaw-dropping, bizarre, and occasionally ...
…
continue reading
Content provided by Docs Who Lift. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Docs Who Lift or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Zepbound versus Wegovy
MP3•Episode home
Manage episode 482242777 series 3363968
Content provided by Docs Who Lift. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Docs Who Lift or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
- Tirzepatide is more effective for weight loss than semaglutide.
- Cost-effectiveness is crucial in prescribing weight loss medications.
- Patients with severe obesity should receive more expensive medications for better outcomes.
- Both medications show significant benefits for obesity-related conditions.
- Long-term studies indicate sustained weight loss with both drugs.
- Gender differences affect weight loss outcomes with these medications.
- Safety profiles show tirzepatide may be better tolerated than semaglutide.
- The need for affordable drug pricing is emphasized.
- Clinical benefits extend beyond weight loss to include metabolic health.
- Future studies are needed to confirm cardiovascular benefits of tirzepatide.
124 episodes
MP3•Episode home
Manage episode 482242777 series 3363968
Content provided by Docs Who Lift. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Docs Who Lift or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
- Tirzepatide is more effective for weight loss than semaglutide.
- Cost-effectiveness is crucial in prescribing weight loss medications.
- Patients with severe obesity should receive more expensive medications for better outcomes.
- Both medications show significant benefits for obesity-related conditions.
- Long-term studies indicate sustained weight loss with both drugs.
- Gender differences affect weight loss outcomes with these medications.
- Safety profiles show tirzepatide may be better tolerated than semaglutide.
- The need for affordable drug pricing is emphasized.
- Clinical benefits extend beyond weight loss to include metabolic health.
- Future studies are needed to confirm cardiovascular benefits of tirzepatide.
124 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.